EP4210662A1 - Compositions de soins buccodentaires - Google Patents

Compositions de soins buccodentaires

Info

Publication number
EP4210662A1
EP4210662A1 EP21734349.0A EP21734349A EP4210662A1 EP 4210662 A1 EP4210662 A1 EP 4210662A1 EP 21734349 A EP21734349 A EP 21734349A EP 4210662 A1 EP4210662 A1 EP 4210662A1
Authority
EP
European Patent Office
Prior art keywords
composition
use according
chloride
extract
quaternary ammonium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21734349.0A
Other languages
German (de)
English (en)
Inventor
Glyn Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever Global IP Ltd
Unilever IP Holdings BV
Original Assignee
Unilever Global IP Ltd
Unilever IP Holdings BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Global IP Ltd, Unilever IP Holdings BV filed Critical Unilever Global IP Ltd
Publication of EP4210662A1 publication Critical patent/EP4210662A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the present invention is concerned with oral care compositions. More particularly, the present invention is concerned with mouthwash compositions.
  • the benefit associated with oral care products are many including prevention and treatment of gingivitis, tooth whitening, breath freshness mitigation of tooth decay and mitigation of tooth sensitivity.
  • the present invention has found that certain oral care compositions can be effective in the for use in the reduction of transmission of SARS-CoV-2 (covid 19).
  • the present invention relates to a composition
  • a composition comprising a quaternary ammonium compound selected from cetylpyridinium chloride (CPC), cetyltrimethylammonium chloride (CTAC), cetyltrimethylammonium bromide (CTAB), benzalkonium chloride (BKC), or mixtures thereof for use in the reduction of transmission of SARS-CoV-2 (covid 19).
  • CPC cetylpyridinium chloride
  • CTAC cetyltrimethylammonium chloride
  • CTAB cetyltrimethylammonium bromide
  • BKC benzalkonium chloride
  • the invention further relates to the use of a quaternary ammonium compound selected from cetylpyridinium chloride (CPC), cetyltrimethylammonium chloride (CTAC), cetyltrimethylammonium bromide (CTAB), benzalkonium chloride (BKC), or mixtures thereof in a composition for the reduction of transmission of SARS-CoV-2 (covid 19).
  • CPC cetylpyridinium chloride
  • CTAC cetyltrimethylammonium chloride
  • CTAB cetyltrimethylammonium bromide
  • BKC benzalkonium chloride
  • a further aspect of the invention relates to the use of a composition comprising a quaternary ammonium compound selected from cetylpyridinium chloride (CPC), cetyltrimethylammonium chloride (CTAC), cetyltrimethylammonium bromide (CTAB), benzalkonium chloride (BKC) and mixtures thereof in the reduction of transmission of SARS-CoV-2 (covid 19).
  • CPC cetylpyridinium chloride
  • CTAC cetyltrimethylammonium chloride
  • CTAB cetyltrimethylammonium bromide
  • BKC benzalkonium chloride
  • the invention also discloses the use of a quaternary ammonium compound selected from cetylpyridinium chloride (CPC), cetyltrimethylammonium chloride (CTAC), cetyltrimethylammonium bromide (CTAB), benzalkonium chloride (BKC) in the manufacture of a medicament for the reduction of transmission of SARS-CoV-2 (covid 19).
  • CPC cetylpyridinium chloride
  • CAC cetyltrimethylammonium chloride
  • CTAB cetyltrimethylammonium bromide
  • BKC benzalkonium chloride
  • Water-insoluble refers to the solubility of a material in water at 25°C and atmospheric pressure being 0.1 % by weight or less.
  • transmission incudes infecting others with human coronavirus SARS-CoV-2 (covid 19) and becoming infected yourself with the virus.
  • compositions according to the invention comprise cetylpyridinium chloride (CPC), cetyltrimethylammonium chloride (CTAC), cetyltrimethylammonium bromide (CTAB), benzalkonium chloride (BKC), or mixtures thereof.
  • CPC cetylpyridinium chloride
  • CAC cetyltrimethylammonium chloride
  • CTAB cetyltrimethylammonium bromide
  • BKC benzalkonium chloride
  • ammonium material comprises cetylpyridinium chloride (CPC).
  • the level of quaternary ammonium compound is from 0.001 to 2 wt% of the total composition, more preferably from 0.01 to 1 wt%.
  • compositions according to the invention preferably comprise at least one extract selected from Aloe Barbadensis leaf, Quercus alba bark, Abies Siberica Juniperus communis fruit, turpentine oil and mixtures thereof.
  • these extracts are aqueous based extracts or carbon dioxide extracts.
  • aqueous based extracts include water and steam based extractions. It is preferable if the aqueous and carbon dioxide based extracts are included from 0.01 to 1 wt% of the total composition.
  • the material listed above were sourced form Russian or European sources.
  • Compositions according to the invention preferably comprises llrtica Dioica Leaf Extract, Chamomilla Recutita Flower Extract, Chelidonium Majus Extract (whole plant), Hypericum Perforatum Flower / Leaf / Stem Extract, Achillea Millefolium Extract (whole plant) and mixtures thereof.
  • Preferred extracts are propylene glycol based extracts.
  • the level of propylene glycol based extract is from 0.1 to 5 wt% of the total composition.
  • the material listed above were sourced from Russian or European sources.
  • the total weight ratio of natural extract to CPC is from 1 : 1 to 20: 1 , more preferably from 2:1 to 15:1.
  • compositions of the invention are in the form of a mouthwash or spray, mouthwashes being particularly preferred.
  • mouthwash generally denotes liquid formulations which are used to rinse the surfaces of the oral cavity and provide the user with a sensation of oral cleanliness and refreshment.
  • the mouthwash is an oral composition that is not intentionally swallowed for purposes of systemic administration of therapeutic agents, but is applied to the oral cavity, used to treat the oral cavity and then expectorated.
  • compositions according to the invention preferably comprise an aqueous base, particularly if it is a mouthwash will usually contain an aqueous continuous phase.
  • the amount of water generally ranges from 70 to 99% by weight based on the total weight of the mouthwash.
  • a mouthwash composition according to the invention will generally contain further ingredients to enhance performance and/or consumer acceptability, such as the humectants and surfactants.
  • the amount of humectant generally ranges from 1.0 to 20%, more preferably from 1 .5 to 5% by weight based on the total weight of the mouthwash.
  • Preferred humectants that are present at the above levels include polyols, more preferred is sorbitol and/or glycerol, glycerol is particularly preferred.
  • the level of ethanol in the total composition is less than 0.1 wt%.
  • compositions of the invention may comprise a preservative, preferred preservatives are benzyl alcohol, and phenoxyethanol.
  • preferred preservatives are benzyl alcohol, and phenoxyethanol.
  • the level of preservative is from 0.1 to 1 wt% of the total composition.
  • composition of the invention may comprise a deposition aid.
  • deposition aid in the context of this invention generally means a material which aids deposition of anti-bacterial agents from the composition. Suitable deposition aids for use in the invention will generally dissolve or disperse in water at a temperature of 25°C.
  • Preferred deposition aids for use in the invention are water soluble.
  • the term “water-soluble” in this particular context generally means that the deposition aid has an aqueous solubility of at least 10g/L at 25°C, and more preferably at least 30g/L at 25°C (where the solubility is determined in unbuffered distilled water). It is particularly preferable that the deposition aid remains water soluble after drying, so that it can be re-dissolved. This prevents undesirable build up of the deposition aid on the teeth after repeated usage of the composition.
  • Suitable deposition aids for use in the invention include polymeric materials, preferably polymeric materials which are water soluble as defined above.
  • Polymeric materials for use as deposition aids in the invention may be naturally or synthetically- derived, and may be ionic or nonionic in nature.
  • polymeric materials are high molecular weight.
  • high molecular weight in this particular context generally means that the polymeric material has a molecular weight of at least 50,000, more preferably at least 500,000 g/mol.
  • a suitable method to determine the molecular weight of such polymeric materials is gel permeation chromatography against a polyethylene glycol standard.
  • Suitable classes of polymeric material for use as deposition aids in the invention include:
  • n Water-soluble, high molecular weight linear homopolymers of ethylene oxide characterised by the general formula H(OCH2CH2) n OH. These materials are generally termed polyethyleneoxides (or alternatively, polyoxyethylenes, or polyethylene glycols). In the general formula, n usually has an average value of at least 2000, preferably at least 50,000.
  • Water-soluble, high molecular weight cellulose ethers such as methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxybutyl methylcellulose, hydroxyethyl ethylcellulose, sodium carboxymethylcellulose, and sodium carboxymethyl hydroxyethylcellulose.
  • a preferred class of polymeric material for use as deposition aids in the invention includes water- soluble, high molecular weight polymers having anionic side groups along the polymer main chain.
  • poly(carboxylic acid) polymers include poly(carboxylic acid) polymers.
  • Poly (carboxylic acid) polymers are typically polymers which include -COOH groups in their structure, or groups which are derived from -COOH groups such as salt, ester or anhydride groups.
  • the poly(carboxylic acid) polymers may include:
  • R 1 is selected from hydrogen, C1.3 alkyl, C1.3 alkoxy or
  • R 1 is hydrogen
  • a preferred type of poly (carboxylic acid) polymer includes adjacent:
  • -[C(R 1 )(COOH)-]- units in its structure for example polymers based on maleic acid, which typically include: -CH(C00H)-CH(C00H)-]- units, and/or salts or esters of such units, or such units in anhydride form in which -COOH groups on adjacent carbon atoms are cyclised to form a ring system.
  • poly(carboxylic acid) polymers may comprise units with pairs of carboxylic acid groups on adjacent polymer chain carbon atoms, for example polymers comprising:
  • R 1 ,R 2 ,R 3 ,R 4 ,R 5 and R 6 are each independently selected from hydrogen, C1.3 alkyl or C1.3 alkoxy.
  • R 1 and R 2 are hydrogen
  • R 3 is hydrogen
  • R 4 is methoxy
  • R 5 and R 6 are hydrogen.
  • Such a poly(carboxylic acid) polymer may be described as the polymer based on a copolymer of methyl vinyl ether and maleic anhydride, and is commercially available for example under the trade name Gantrez®.
  • a particularly preferred example of such a polymer comprises:
  • Such polymers may be linear or cross-linked. More preferably the polymer is linear. Polymers of this type are commercially available for example under the trade name Gantrez® S. Most preferably such a polymer has a molecular weight of at least 500,000 g/mol (e.g. Gantrez® S-96), ideally at least 1 ,000,000 g/mol (e.g. Gantrez® S-97).
  • Alternative polymers which may be used comprise the units as described above in anhydride form, i.e. in which the two adjacent -COOH groups are cyclised to form a ring system.
  • Such polymers are commercially available under the tradename Gantrez® AN, e.g. Gantrez® AN- 119, Gantrez® AN-903, Gantrez® AN- 139 and Gantrez® AN-169.
  • a metal salt of a Group I or Group II metal such as either sodium or calcium, or a mixed sodium-calcium salt.
  • Such polymers are commercially available under the tradename Gantrez® MS, e.g. Gantrez® MS-955.
  • Such polymers are commercially available under the tradename Gantrez® ES, e.g. Gantrez® ES-225 or Gantrez® ES-425.
  • the amount of deposition aid (as defined above) in compositions of the invention suitably ranges from 0.001 to 5.0%, preferably from 0.005 to 4.0%, more preferably from 0.01 to 2.0% by total weight deposition aid (as defined above) based on the total weight of the composition.
  • the composition comprises an acid anhydride polymers, particularly preferred are copolymers of maleic anhydride with methyl vinylether, in which the anhydride moiety may be in a partially or fully hydrolysed or alcoholysed form.
  • the composition may contain low levels of surfactant based on the total weight of the composition. If present, the surfactant is preferably present at levels of less than 3.0 wt% of the total composition, more preferably at levels less than 2.0 wt%, most preferably at levels of less than 1 .5 wt%.
  • Suitable surfactants for use in the invention comprises nonionic surfactants, such as polyethoxylated fatty acid sorbitan esters, ethoxylated fatty acids, esters of polyethylene glycol, ethoxylates of fatty acid monoglycerides and diglycerides, and ethylene oxide/propylene oxide block polymers.
  • nonionic surfactants are ethoxylated polyethylene glycol esters of castor oil, particularly PEG 40 hydrogenated castor oil.
  • Suitable surfactants include amphoteric surfactants, such as betaines or sulphobetaines. Mixtures of any of the above described materials may also be used.
  • composition is free of anionic surfactants.
  • compositions of the present invention may also contain further optional ingredients customary in the art such as fluoride ion sources, anticalculus agents, buffers, flavouring agents, stability agents such as EDTA, sweetening agents, colouring agents, opacifying agents, antisensitivity agents and antimicrobial agents.
  • fluoride ion sources such as fluoride ion sources, anticalculus agents, buffers, flavouring agents, stability agents such as EDTA, sweetening agents, colouring agents, opacifying agents, antisensitivity agents and antimicrobial agents.
  • compositions typically involves application of the composition to the oral cavity, for a recommended time period before being expectorated. Preferred application times are from 10 to 50 seconds.
  • Mouthwash compositions having the ingredients shown in Table 1 below were prepared.
  • the ASTM (American Society for Testing and Measurement) have produced recommendations on SARS-CoV-2 surrogates, these include the Human Corona virus Strain 229E (ATCC #VR-740), This surrogate was used to demonstrate the effectiveness of the present invention.
  • Example 1 and a commercial mouthwash comprising 15.7 wt% alcohol were evaluated for virucidal activity against Human Coronavirus Strain CoV-229E (ATCC #VR-740) following a standard suspension ‘time to kill’ protocol based upon ASTM International Standard E1052-20.
  • the mean Iog10 reduction was calculated as the difference in TCID50 between the test product treatment and virus recovery control. % reduction was calculated using TCID50 for the test treatment and virus recovery control. 3 replicates were completed.
  • Example 1 of the invention applied for 30 and 60 seconds, resulted in greater than 3 log reduction of viral count of a SARS-CoV-2 surrogate, CoV- SARS 229E.
  • a comparative Example containing 15.7% ethanol demonstrated poor virucidal action with only 0.17 and 0.33 log reductions, respectively.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition comprenant un composé d'ammonium quaternaire choisi parmi le chlorure de cétylpyridinium (CPC), le chlorure de cétyltriméthylammonium (CTAC), le bromure de cétyltriméthylammonium (CTAB), le chlorure de benzalkonium (BKC), ou des mélanges de ceux-ci, destinée à être utilisée dans la réduction de la transmission du SRAS-CoV-2 (COVID-19).
EP21734349.0A 2020-09-08 2021-06-23 Compositions de soins buccodentaires Pending EP4210662A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20195030 2020-09-08
PCT/EP2021/067261 WO2022053194A1 (fr) 2020-09-08 2021-06-23 Compositions de soins buccodentaires

Publications (1)

Publication Number Publication Date
EP4210662A1 true EP4210662A1 (fr) 2023-07-19

Family

ID=72432716

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21734349.0A Pending EP4210662A1 (fr) 2020-09-08 2021-06-23 Compositions de soins buccodentaires

Country Status (4)

Country Link
EP (1) EP4210662A1 (fr)
CN (1) CN116157113A (fr)
BR (1) BR112023001199A2 (fr)
WO (1) WO2022053194A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994262A (en) * 1988-10-14 1991-02-19 The Procter & Gamble Company Oral compositions
CN1287803C (zh) * 2000-06-30 2006-12-06 宝洁公司 促进全身健康的局部口腔组合物及其应用
US20050100601A1 (en) * 2003-11-07 2005-05-12 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
EP1686993B1 (fr) * 2003-11-07 2011-01-12 Viratox, L.L.C. Activites virocides d'une composition comprenant du chlorure de cetylpyridinium et de l'acide citrique
RU2598740C1 (ru) * 2015-07-30 2016-09-27 Общество с ограниченной ответственностью "Научно-производственный центр "Джи-Фарм" Лечебно-профилактический ополаскиватель для десен

Also Published As

Publication number Publication date
WO2022053194A1 (fr) 2022-03-17
CN116157113A (zh) 2023-05-23
BR112023001199A2 (pt) 2023-03-28

Similar Documents

Publication Publication Date Title
US10561590B2 (en) Dentifrice compromising zinc-amino acid complex and phosphates
RU2700691C2 (ru) Композиции для ухода за полостью рта и способы их применения
RU2390329C2 (ru) Пероральные композиции, содержащие окисленную камелию
AU774885B2 (en) Stable hydrogenated lupulone antibacterial oral compositions
TWI404544B (zh) 含珠粒之口腔保健組成物
RU2597159C2 (ru) Продукт для ухода за полостью рта и способы его применения и изготовления
CN105828796B (zh) 牙齿美白口腔护理产品
JP2013542250A (ja) オーラルケア製品ならびにその使用方法および製造方法
US20220133607A1 (en) Oral Care Composition
AU2024204312A1 (en) Oral care composition
EP4210662A1 (fr) Compositions de soins buccodentaires
US20230355668A1 (en) Hydroxyapatite composition for treatment and/or prevention of a virus infection
EP4281190A1 (fr) Composition de soin buccal
CN116761581A (zh) 口腔护理组合物
CN113329730A (zh) 用于口腔护理组合物的防腐剂系统

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230104

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)